Guardant Health, Inc.
A precision-oncology company that spots cancer with simple blood tests, including the Shield test, the first FDA-approved blood test for colorectal cancer screening, plus the Guardant360 CDx for guiding treatment and Guardant Reveal for watching for recurrence. Co-founded in 2012 by two Stanford PhDs, Helmy Eltoukhy and AmirAli Talasaz, it was built on the idea of catching cancer's genetic "signature" floating in the bloodstream. Its Shield test was designed to make cancer screening as easy as a routine blood draw, avoiding the preparation many people dread.
Granted 414.2K · Sold 657.5K
Granted 159.4K · Sold 490.6K
Granted 71.6K · Sold 28.4K
Granted 68.6K
Granted 97.4K · Sold 55.9K
Granted 129.7K · Sold 85.4K
Granted 101.1K · Bought 600 · Sold 51.6K
Granted 64.4K · Sold 39.0K
Granted 4.2K
Granted 103.4K · Sold 77.6K
Granted 4.3K · Sold 1.6K
Granted 14.2K · Sold 10.1K
Granted 5.7K · Sold 9.3K
Granted 6.7K · Sold 3.1K
Granted 9.7K
Granted 33.7K · Sold 35.5K
Granted 10.5K · Sold 8.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Talasaz AmirAliCo-Chief Executive Officer, Director · 56 transactions | — | 6.65M | 414.2K | — | 657.5K |
| Eltoukhy HelmyCo-Chief Executive Officer, Director · 35 transactions | — | 6.16M | 159.4K | — | 490.6K |
| Chudova DaryaChief Technology Officer · 29 transactions | — | 160.2K | 71.6K | — | 28.4K |
| Eagle CraigChief Medical Officer · 22 transactions | +88.1% | 72.4K | 68.6K | — | — |
| Freeman ChrisChief Commercial Officer · 37 transactions | +22.5% | 61.7K | 97.4K | — | 55.9K |
| Bell Michael BrianChief Financial Officer · 40 transactions | +9.9% | 48.5K | 129.7K | — | 85.4K |
| Kalia KumudChief Information Officer · 40 transactions | +123.9% | 41.4K | 101.1K | 600 | 51.6K |
| Saia John G.Chief Legal Officer · 34 transactions | -20% | 37.0K | 64.4K | — | 39.0K |
| Gadde VijayaDirector · 1 transaction | +17.3% | 28.5K | 4.2K | — | — |
| Monroe Terilyn J.Chief People Officer · 26 transactions | -21.7% | 21.0K | 103.4K | — | 77.6K |
| Potter Myrtle SDirector · 6 transactions | +15% | 21.0K | 4.3K | — | 1.6K |
| Joyce Meghan V.Director · 8 transactions | +36.4% | 15.4K | 14.2K | — | 10.1K |
| Krognes Steve E.Director · 12 transactions | -19.7% | 14.4K | 5.7K | — | 9.3K |
| Tariq MusaDirector · 20 transactions | +48.1% | 11.0K | 6.7K | — | 3.1K |
| Mignone RobertoDirector · 11 transactions | — | 10.0K | 9.7K | — | — |
| Clark Ian TDirector · 8 transactions | -18.1% | 8.1K | 33.7K | — | 35.5K |
| Hidalgo Medina ManuelDirector · 25 transactions | +68.2% | 5.1K | 10.5K | — | 8.5K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: -1.55M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.